Rezdiffra (Resmetirom) and Warfarin Interaction: What Every Woman Needs to Know

The Short Answer: Yes, Resmetirom and Warfarin Interact, and the Risk Is Real

Taking resmetirom alongside warfarin raises your warfarin exposure and can push your INR into dangerous territory. The FDA prescribing information for Rezdiffra explicitly flags warfarin as a drug that requires additional monitoring during co-administration. This is not a theoretical concern. Warfarin has a narrow therapeutic index, meaning the gap between "not enough anticoagulation" and "too much" is small, and any drug that interferes with its clearance requires a concrete clinical response, not just a note in the chart.

For women specifically, the combination comes up most often in two situations: postmenopausal women who are on warfarin for atrial fibrillation or venous thromboembolism and who are newly diagnosed with metabolic-associated steatohepatitis (MASH), and premenopausal women with MASH who are anticoagulated for clotting disorders such as antiphospholipid syndrome. Both groups need an individualized monitoring plan before the first resmetirom dose is swallowed.

How Resmetirom Works, and Why It Affects Warfarin

Resmetirom's mechanism of action

Resmetirom is a selective thyroid hormone receptor beta (THR-beta) agonist. It activates THR-beta in the liver, which reduces intrahepatic fat, improves mitochondrial function, and lowers fibrosis-driving inflammation. In the MAESTRO-NASH trial, 26% of patients on the 100 mg dose achieved MASH resolution without worsening fibrosis, compared with 10% on placebo, which was the trial result that drove FDA approval in March 2024.

Why CYP2C9 matters for warfarin

Warfarin is a racemic mixture. The S-enantiomer is three to five times more pharmacologically active than the R-enantiomer, and the S-enantiomer is metabolized almost entirely by CYP2C9. Resmetirom inhibits CYP2C9 in vitro, and its own metabolism is partly dependent on the same enzyme pathway. When CYP2C9 is inhibited, S-warfarin clears more slowly, plasma concentrations rise, and anticoagulant effect increases, sometimes sharply.

The Rezdiffra FDA label categorizes warfarin as a sensitive CYP2C9 substrate and instructs prescribers to monitor INR more frequently whenever resmetirom is initiated, discontinued, or dose-adjusted. No fixed percentage dose reduction is mandated because the magnitude of INR change varies with CYP2C9 genotype, baseline warfarin dose, diet, and other co-medications.

The pharmacodynamic layer

Beyond pharmacokinetics, MASH itself compromises hepatic synthesis of vitamin K-dependent clotting factors (II, VII, IX, X). As resmetirom reduces liver inflammation and improves hepatocyte function over weeks to months, clotting factor synthesis may increase, which would theoretically pull INR back down. This creates a moving target: early in treatment, the CYP2C9 inhibition effect tends to dominate (INR rises); later, as liver function improves, the two effects partially offset each other. Clinicians managing this combination need to track INR longitudinally rather than assuming a single dose adjustment will hold.

Severity Classification and What the Evidence Base Actually Shows

Interaction databases and guideline classifications

Major drug interaction databases, including Lexicomp and Clinical Pharmacology, rate the resmetirom-warfarin combination as a significant or major interaction requiring monitoring and possible dose modification. The FDA label does not use a severity tier but places warfarin in the list of drugs requiring specific action, which in practice aligns with a "major" designation.

What the clinical trial data do and do not tell us

Warfarin's use in the MAESTRO-NASH trial was not systematically reported as a co-medication subgroup. This is an evidence gap worth naming directly. The trial enrolled 966 patients across 37 weeks for the histological endpoints, and anticoagulated patients were not excluded as a group. Real-world warfarin co-administration data for resmetirom does not yet exist in the published literature as of early 2025. The interaction prediction comes from in vitro CYP2C9 inhibition data and the established pharmacology of S-warfarin, not from a dedicated drug-drug interaction study in humans. Women and clinicians deserve to know this distinction.

CYP2C9 genotype changes the picture

Roughly 30% of people carry at least one reduced-function CYP2C9 allele (CYP2C9*2 or *3 being the most common in people of European ancestry). If you already have reduced CYP2C9 activity, you are more sensitive to any inhibitor of that enzyme, and your INR response to the combination will likely be larger than in a person with two wild-type alleles. Some anticoagulation clinics now offer CYP2C9 genotyping when managing complex warfarin interactions, and that is worth discussing with your prescriber if you are in this situation.

The Monitoring Plan: What Should Actually Happen

The following monitoring framework synthesizes the FDA label instruction, established warfarin management principles from ACCP antithrombotic guidelines, and clinical pharmacology principles for CYP2C9 inhibitors. No single published guideline covers this exact combination, so this framework represents the reasoned integration of those sources.

Before starting resmetirom

1. Check your current INR within 5 to 7 days before your first resmetirom dose. You want a confirmed stable baseline.
2. Review your current warfarin dose and recent INR trend. If your INR has been fluctuating, stabilize it first if possible.
3. Tell your anticoagulation clinic, hematologist, or cardiologist that you are starting resmetirom. They should be the ones adjusting your warfarin, not left to discover the change at your next routine appointment.

During the first four to eight weeks

• Check INR at 7 days after your first resmetirom dose.
• Check again at 14 days.
• If the INR is outside your target range, adjust warfarin and recheck in 7 to 10 days.
• Once your INR has been stable at two consecutive measurements on the new warfarin dose, you can return to your usual monitoring interval.

When resmetirom is stopped

The inhibitory effect on CYP2C9 will diminish over days as resmetirom clears. Warfarin levels may fall, and your INR may drop below therapeutic range, increasing clot risk. Check INR within 5 to 7 days of stopping resmetirom and again at 14 days.

When resmetirom dose changes

The approved doses of resmetirom are 80 mg and 100 mg once daily. If your dose is titrated (most patients start at 80 mg), repeat the same early-monitoring schedule used at initiation.

Who This Combination Is Right For, and Who Should Pause

Women who can be managed on both drugs

Most women who need both resmetirom and warfarin can take them together with appropriate monitoring. The combination is not contraindicated, and withholding MASH treatment from someone who also needs anticoagulation is not justified simply because the INR requires closer attention. Good candidates for co-administration include:

• Postmenopausal women with biopsy-confirmed MASH (F2-F3) who are stable on warfarin for atrial fibrillation or prior VTE.
• Women with metabolic syndrome and MASH who are anticoagulated for antiphospholipid antibody syndrome, provided they have reliable access to INR monitoring.

Women who need a more careful conversation first

• Women whose INR is already labile (three or more out-of-range values in the past 12 weeks) may find the additional variability from a CYP2C9 inhibitor hard to manage. Switching to a direct oral anticoagulant (DOAC) that does not interact with resmetirom should be discussed with your cardiologist or hematologist before starting resmetirom.
• Women who have poor access to regular blood draws for INR monitoring. A point-of-care home INR device can solve this problem for many patients; this is worth asking about.

Switching from warfarin to a DOAC

For patients who need both anticoagulation and resmetirom, switching from warfarin to a DOAC such as apixaban or rivaroxaban is a real option. Resmetirom's effect on DOAC pharmacokinetics is less studied than its effect on warfarin, but apixaban is metabolized primarily by CYP3A4, not CYP2C9, which largely avoids the interaction. The FDA label for Rezdiffra does not flag apixaban as a drug of concern. Any anticoagulant switch must be made by the clinician managing your anticoagulation, not independently.

Pregnancy, Lactation, and Contraception: A Required Section

Both resmetirom and warfarin are contraindicated in pregnancy. If there is any possibility you could become pregnant, this section is not optional reading.

Resmetirom in pregnancy

Resmetirom is contraindicated in pregnancy. Animal reproductive toxicity studies showed embryofetal harm at doses relevant to human exposure. There are no adequate human data. Because MASH requiring resmetirom therapy is most common in women of perimenopausal or postmenopausal age, many women taking this drug will not need contraception. For premenopausal women with MASH who are prescribed resmetirom, the FDA label requires the use of effective contraception during treatment.

Warfarin in pregnancy

Warfarin crosses the placenta and is teratogenic, particularly during weeks 6 through 12 of gestation, when it causes warfarin embryopathy (nasal hypoplasia, stippled epiphyses, limb abnormalities). ACOG Practice Bulletin No. 196 documents fetal risks in detail and recommends switching to low-molecular-weight heparin during pregnancy for women who require anticoagulation. Warfarin also carries a risk of fetal intracranial hemorrhage in the second and third trimesters.

If you are a premenopausal woman on warfarin for anticoagulation who is considering resmetirom, pregnancy planning discussions must happen before you start either drug.

Lactation

The FDA label for resmetirom states that there are no data on the presence of resmetirom in human milk, its effects on the breastfed infant, or its effects on milk production. Given the absence of safety data and the known animal toxicity signal, breastfeeding is not recommended during resmetirom treatment.

Warfarin is considered compatible with breastfeeding by LactMed and supported by ACOG guidance: it does not transfer into breast milk in clinically significant amounts. But since resmetirom is not compatible with breastfeeding, a woman who needs resmetirom cannot breastfeed regardless of the warfarin question.

Life-stage summary for pregnancy and lactation

• Reproductive years, trying to conceive: Do not start resmetirom. Discuss MASH management options that are pregnancy-compatible with your hepatologist and OB-GYN.
• Pregnant: Resmetirom is contraindicated. Warfarin should be replaced with LMWH per ACOG guidance.
• Postpartum and breastfeeding: Resmetirom is not recommended. Warfarin is compatible with breastfeeding but moot in this context.
• Perimenopause and postmenopause: Most women taking resmetirom will fall here. Contraception requirements may still apply in perimenopause if menstruation has not fully ceased for 12 consecutive months.

Resmetirom's Other Drug Interactions Worth Knowing

Warfarin is not the only medication with a meaningful interaction with resmetirom. The FDA label identifies several other interaction categories relevant to women with MASH:

Statins

Resmetirom inhibits OATP1B1 and OATP1B3 hepatic uptake transporters. Statins such as rosuvastatin, atorvastatin, and simvastatin are substrates of these transporters. Co-administration can raise statin plasma concentrations and increase the risk of myopathy and rhabdomyolysis. Women with MASH are frequently on statins for metabolic syndrome management. The label recommends using the lowest effective statin dose and monitoring for muscle symptoms.

P-glycoprotein substrates

Resmetirom inhibits P-glycoprotein (P-gp) in vitro. Digoxin, a narrow-therapeutic-index P-gp substrate, should have its levels monitored when resmetirom is started or stopped.

BCRP substrates

Resmetirom inhibits BCRP, which affects the bioavailability of drugs like methotrexate and rosuvastatin. Women being treated for autoimmune conditions with methotrexate should flag this to their rheumatologist.

MASH in Women: Why This Drug Matters and Why the Evidence Gap Hurts

MASH affects an estimated 1.5 to 6.5% of the US adult population, and women account for a substantial proportion of cases, particularly postmenopausal women in whom estrogen loss removes a protective effect on hepatic lipid metabolism. Estrogen reduces hepatic de novo lipogenesis and promotes fatty acid oxidation. After menopause, this protection disappears, contributing to accelerated fat accumulation in the liver.

Women were enrolled in MAESTRO-NASH at roughly equal rates to men, which is a positive feature of that trial. Sex-stratified efficacy data have not been published separately as of early 2025, which means we cannot say with certainty whether women respond to resmetirom at the same rates or with the same magnitude of histological improvement as men. That is an evidence gap. The trial did not enrich for postmenopausal women or stratify by hormonal status, so the interaction between resmetirom's THR-beta activity and estrogen-depleted liver physiology remains unexplored in published data.

PCOS is another relevant condition. Women with PCOS have higher rates of MASH than age-matched controls, driven by hyperinsulinemia, androgen excess, and central adiposity. If a younger woman with PCOS and early MASH is being considered for resmetirom, she is also more likely to be in reproductive years where contraception requirements must be addressed explicitly.

What to Tell Your Care Team

When you see your hepatologist, cardiologist, anticoagulation clinic, or primary care provider, bring the following points to the conversation:

1. Ask specifically: "Is resmetirom going to affect my warfarin INR, and who will manage my INR adjustments?"
2. Identify one clinician as the point person for warfarin management during the resmetirom initiation period. Fragmented care between a hepatologist and a cardiologist, with neither owning the INR, is a common failure mode.
3. Confirm your INR target range and ask what INR level would prompt an urgent call versus a routine appointment.
4. If home INR monitoring is not already part of your routine, ask whether a point-of-care coagulometer would be appropriate.
5. Ask whether switching from warfarin to a DOAC has ever been considered for your indication, and whether the resmetirom interaction changes that calculus.

Frequently Asked Questions